- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Dna Isolation.
Displaying page 1 of 1.
EudraCT Number: 2014-001501-41 | Sponsor Protocol Number: 156-13-208 | Start Date*: 2016-01-16 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
Full Title: A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal... | ||
Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD), Patients with Increased Risk of Liver Injury | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002322-11 | Sponsor Protocol Number: ARTemis | Start Date*: 2009-04-29 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust [...] | ||
Full Title: ARTemis : Avastin® Randomised Trial with nEo-adjuvant cheMotherapy for patients wIth early breaSt cancer | ||
Medical condition: HER2 negative invasive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-024359-99 | Sponsor Protocol Number: M11-891 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects with Diabetic Neuropathic Pain | |||||||||||||
Medical condition: Diabetic Neuropathic Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004869-88 | Sponsor Protocol Number: HS2116100 | Start Date*: 2016-12-21 |
Sponsor Name:GlaxoSmithKline K.K. (GSK) | ||
Full Title: A multicenter, open-label study to evaluate preventive efficacy for herpes simplex virus infection and safety of 256U87 (valaciclovir hydrochloride) in adult and pediatric hematopoietic stem cell t... | ||
Medical condition: Herpes simplex virus (HSV) infection before and after hematopoietic stem cell transplantation. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-000178-31 | Sponsor Protocol Number: TREATMENT-patients | Start Date*: 2018-05-23 |
Sponsor Name:Fundación para la Investigación e Innovación Biosanitaria de Asturias (FINBA) | ||
Full Title: Metabolic Dysfunctions Associated with Pharmacological Treatment of Schizophrenia | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003102-26 | Sponsor Protocol Number: HIV-CORE007 | Start Date*: 2021-07-14 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Therapeutic vaccination: A Phase I/II Randomized, Placebo-Controlled Trial of ChAdOx1.tHIVconsvX prime-MVA.tHIVconsvX Boost Vaccination Regimen in Early-treated durably-controlling HIV-1 positive A... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004429-15 | Sponsor Protocol Number: GEM-1402 | Start Date*: 2016-02-16 | |||||||||||
Sponsor Name:GRUPO ESPAÑOL MULTICISPLINAR DE MELANOMA | |||||||||||||
Full Title: Phase II multicente, non randomized, open label trial of nivolumab in combination with ipilimumab in subjects with previously untreated metastatic uveal melanoma. | |||||||||||||
Medical condition: Metastatic uveal melanoma non suitable for radical resection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003185-27 | Sponsor Protocol Number: C17-02 | Start Date*: 2018-04-18 | |||||||||||
Sponsor Name:GERCOR | |||||||||||||
Full Title: A non-comparative randomized 2:1 phase II study of docetaxel, cisplatin, and 5-fluorouracil in combination or not with atezolizumab in patients with metastatic or unresectable locally advanced squa... | |||||||||||||
Medical condition: Metastatic or unresectable locally advanced squamous anal carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016489-10 | Sponsor Protocol Number: TPF-C-HIT | Start Date*: 2010-08-23 |
Sponsor Name:University of Heidelberg | ||
Full Title: Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanc... | ||
Medical condition: The study is a phase II study of induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003569-36 | Sponsor Protocol Number: D9571C00001 | Start Date*: 2022-05-20 | |||||||||||
Sponsor Name:ASTRAZENECA AB | |||||||||||||
Full Title: A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with R... | |||||||||||||
Medical condition: Relapse/Refractory Classical Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002284-18 | Sponsor Protocol Number: UC-0140/1711 | Start Date*: 2017-12-02 |
Sponsor Name:UNICANCER | ||
Full Title: A randomized phase 2 study in patients with triple-negative, androgen receptor positive locally advanced (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine | ||
Medical condition: Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally advanced (unresectable) or metastatic breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Ongoing) BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006161-84 | Sponsor Protocol Number: Version 2.1 | Start Date*: 2009-06-17 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: ARTiST - Aromasin Randomised Trial +/- Sutent as neoadjuvant Therapy for post-menopausal women with breast cancer. | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001154-14 | Sponsor Protocol Number: Vonoprazan-2001 | Start Date*: 2016-05-23 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd | |||||||||||||
Full Title: A Randomized, Double-Blind, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once Daily Oral Vonoprazan 20 mg or Vonoprazan 40 mg Compared to Esomeprazole 40 mg for the Treatm... | |||||||||||||
Medical condition: Gastro-Esophageal Reflux Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) EE (Completed) BE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003298-28 | Sponsor Protocol Number: M06-822 | Start Date*: 2007-05-23 | |||||||||||
Sponsor Name:Abbott Laboratories Limited (Queenborough, Kent, ME11 5EL, England) | |||||||||||||
Full Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies. | |||||||||||||
Medical condition: Small cell lung carcinoma (SCLC) (North America or UK) and other non-hematological malignancies (North America only). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002313-41 | Sponsor Protocol Number: CRC2021-02 | Start Date*: 2023-06-06 | ||||||||||||||||
Sponsor Name:CENTRO RICERCHE CLINICHE DI VERONA | ||||||||||||||||||
Full Title: A PHASE 2, MULTICENTER, OPEN LABEL, CLINICAL TRIAL EVALUATING SAFETY AND ACTIVITY OF NIVOLUMAB/IPILIMUMAB AND CHEMOTHERAPY COMBINATION IN ADVANCED NSCLC PATIENTS WITH HIV, HBV, HCV AND POST-ACUTE S... | ||||||||||||||||||
Medical condition: advanced non-small-cell lung cancer (NSCLC) (both squamous and non-squamous) in patients with chronic viral infections or sequalae from Sars-Cov2 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005220-26 | Sponsor Protocol Number: ACE-LY-308 | Start Date*: 2017-05-16 | |||||||||||
Sponsor Name:Acerta Pharma BV | |||||||||||||
Full Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Un... | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) DE (Ongoing) BE (Ongoing) ES (Ongoing) CZ (Ongoing) GR (Ongoing) PL (Ongoing) FR (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005437-53 | Sponsor Protocol Number: ITCC053 | Start Date*: 2016-11-03 |
Sponsor Name:Erasmus Medical Center | ||
Full Title: A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Study ITCC 053 | ||
Medical condition: Malignancies carrying a genetic alteration of ALK, MET or ROS1 | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DE (Ongoing) IE (Completed) ES (Ongoing) DK (Trial now transitioned) IT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.